Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving their cancer treatments.
The deal, announced late Monday, sent UK-listed shares of AstraZeneca 1.9% higher to a two-month high.
Its US-listed stock was also up about 1.3% in premarket trading.
AstraZeneca will purchase preferred shares in Summit at an equivalent price of $18.36 per common share, an 18.6% premium to Summit’s Monday closing price of $15.48.
The transaction is expected to close by the end of the week and will give AstraZeneca an interest equivalent to about 12% of Summit’s stock, or 10.6% on a fully diluted basis.
The investment represents a major strategic endorsement of Summit’s ivonescimab, a next-generation cancer treatment licensed from China’s Akeso.
AstraZeneca gains access to ivonescimab
Ivonescimab is designed to target two biological pathways at the same time.
It blocks PD-1, a protein cancer cells can exploit to evade the immune system, while also inhibiting VEGF, which tumors use to develop the blood vessels needed for growth.
The approach, known as a PD-1/VEGF bispecific, has attracted growing interest as drugmakers search for alternatives and additions to existing immunotherapies.
Under the agreement, Summit and AstraZeneca will begin clinical testing of ivonescimab alongside AstraZeneca’s experimental cancer treatment sonesitatug vedotin in certain gastrointestinal cancers.
The companies also intend to conduct additional studies combining ivonescimab with multiple AstraZeneca medicines.
The potential combinations include the company’s antibody-drug conjugates, or ADCs, which are designed to deliver cancer-killing drugs more directly to tumor cells.
Each company will retain development and commercial rights to its respective medicines.
Goldman Sachs analyst Salveen Richter said the non-exclusive partnership gives Summit access to AstraZeneca’s ADC pipeline as the company evaluates which ivonescimab combinations could work best for individual cancer types.
Analysts see strategic value for both companies
Several Wall Street analysts viewed the transaction as strategically significant for both companies.
JPMorgan, which has an Overweight rating on Summit, said the investment would allow AstraZeneca to test ivonescimab alongside its own Sone-V treatment and broader oncology portfolio, including ADCs, according to Bloomberg.
The brokerage estimates AstraZeneca will hold rights equivalent to about 12% of Summit once the investment is completed.
Citi also welcomed the agreement, saying it fits with AstraZeneca’s efforts to build its ADC portfolio into a foundation for future oncology combinations.
“This deal aligns with AstraZeneca’s effort to position its expanding ADC portfolio as the backbone of its future oncology regimen,” Citi analyst John Yung wrote in a note.
“We view the transaction as a strong external validation of ivonescimab as well as the PD-1/VEGF bispecific asset class,” he added.
Barclays analyst James Gordon said the deal gives AstraZeneca access to an emerging mechanism and brings the company closer to US peers developing similar approaches.
“We had seen a VEGF bispecific deal as all the more likely, following discontinuation of Astra’s volrustomig bispecific last month, which left Astra’s solid tumour pipeline looking a little thinner, and which this now helps address,” Gordon added.
UBS maintained a Buy rating on AstraZeneca with a 15,200p target while Jefferies has a Buy rating and 17,500p target.
Summit gets capital without giving up control
For Summit, the agreement provides a substantial cash injection while allowing the company to retain control of its lead drug.
Evercore ISI analyst Cory Kasimov described the transaction as a validating buy-in from a global cancer-treatment company and said it gives Summit additional financial resources while preserving strategic flexibility.
Cantor Fitzgerald analyst Eric Schmidt similarly highlighted the combination of capital and clinical expertise.
“The infusion of capital and clinical capabilities that AstraZeneca is providing will enable Summit to go bigger, faster and capture an even bigger slice of the pie,” Schmidt said, adding that the arrangement also makes strategic sense for AstraZeneca.
Jefferies raised its price target on Summit to $30 from $25 while maintaining a Buy rating, citing the cash infusion and strategic validation from AstraZeneca.
The firm said cash runway and strategic interest were key considerations for investors and that the transaction addresses both.
Jefferies called the agreement “strategically smart”, arguing that AstraZeneca gains exposure to ivonescimab without taking on the substantially greater risk of acquiring Summit outright.
HARMONi-3 trial becomes a key catalyst
Despite the immediate market reaction, the longer-term investment case remains tied to clinical data.
UBS noted that emerging evidence suggests PD-1/VEGF bispecific drugs could outperform existing PD-1 treatments in some cancers.
The firm also highlighted that Summit confirmed AstraZeneca had not seen unpublished results from its HARMONi-3 trial.
The phase III study is testing ivonescimab in advanced lung cancer and is expected to provide an important test of the drug’s potential.
Jefferies expects the first major readout before the end of 2026.
The fact that AstraZeneca has agreed to invest before that data arrives also allows the larger drugmaker to gain exposure to the treatment while limiting the financial risk associated with a full acquisition.
AstraZeneca will receive exposure to ivonescimab while Summit gains access to the resources and clinical capabilities of a global oncology player.
Goldman Sachs reiterated a Buy rating and a $41 price target on Summit following the announcement.
The agreement therefore gives Summit more financial firepower as it advances ivonescimab trials, while AstraZeneca gains an opportunity to explore whether the drug’s dual-target mechanism can complement its expanding cancer portfolio.
The post Summit Therapeutics jumps 20% after AstraZeneca’s $2 billion bet: what it signals appeared first on Invezz